Detalle Publicación

CAR-t cells for the treatment of lung cancer

Autores: Chocarro, L.; Arasanz, H. (Autor de correspondencia); Fernández-Rubio, L.; Blanco Palmeiro, Ester; Echaide, M.; Bocanegra, A.; Teijeira, L.; Garnica, M.; Morilla, I.; Martínez-Aguillo, M.; Pineiro-Hermida, S.; Ramos, P.; Lasarte Sagastibelza, Juan José; Vera, R.; Kochan, G.; Escors, D.
Título de la revista: LIFE
ISSN: 2075-1729
Volumen: 12
Número: 4
Páginas: 561
Fecha de publicación: 2022
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies. However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses. The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy. Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.